Objective: The loss of estrogen in mRen2.Lewis rats leads to an exacerbation of diastolic dysfunction. Because specific neuronal nitric oxide synthase (nNOS) inhibition reverses renal damage in the same model, we assessed the effects of inhibiting neuronal nitric oxide on diastolic function, left ventricular remodeling, and the components of the cardiac nitric oxide system in ovariectomized (OVX) and sham-operated mRen2.Lewis rats treated with N 5 -(1-imino-3-butenyl)-L-ornithine (L-VNIO; 0.5 mg/kg per day for 28 d) or vehicle (saline).
R esearch directed to explore the underlying mechanisms associated with the development and progression of heart failure is an important area of investigation, as the incidence of this disease is reaching epidemic proportions. 1 Recent data of lengthened survival in male patients with heart failure have not shown comparable benefits in women. 2, 3 This is partly because research conducted to date, as well as current treatment approaches, target systolic dysfunction, the more common type of heart failure in men as opposed to diastolic dysfunction in women. In fact, some estimates claim that 75% of women with diastolic heart disease are those older than 65 years. 4, 5 The prognosis for these women is severe because there is a significant increase in hospitalizations compared with women with systolic heart failure, 1, 6 and women with diastolic heart disease yield death rates greater than 20%. 7, 8 The mechanisms underlying diastolic dysfunction, the precursor of heart failure with normal ejection fraction or diastolic heart failure, are poorly understood, particularly in older women. The loss of estrogen after menopause has been linked to the development of hypertension and left ventricular (LV) hypertrophy, 9, 10 two risk factors for diastolic dysfunction. 11 However, estrogen therapy remains controversial given that data from the Women's Health Initiative have not shown protective cardiovascular benefits in postmenopausal women receiving estrogen therapy. 12 In addition, the precise mechanism by which estrogen acts in women to give cardioprotection is not completely clear, although data demonstrate that estrogen modulates the production of nitric oxide (NO). 13<15 A role of the NO system in the progression of heart failure in postmenopausal women may be related to estradiol up-regulation of endothelial NO synthase (eNOS) by stimulation of serine/ threonine protein kinase Akt (protein kinase B). 16 The actions of eNOS and neuronal NOS (nNOS) have profound impacts on diastolic function by affecting NO bioavailability. 17 Furthermore, dysregulation of the NOS system may contribute to diastolic dysfunction based on several lines of evidence, including (1) regulated production of nNOS by estrogen 18<21 and (2) the observation that estrogen receptor A mediates increases in cardiomyocyte eNOS levels. 22 Surgical depletion of endogenous estrogen in experimental models results in significant changes in blood pressure and cardiovascular function. In our prior study, the development of diastolic dysfunction, interstitial fibrosis, and increased serum aldosterone was accelerated in female hypertensive mRen2.Lewis after oophorectomy. 23 The mRen2.Lewis strain, which expresses the mouse renin 2 (mRen2) gene in various tissues, is a congenic model of angiotensin IIYdependent hypertension produced by the successive backcross of the (mRen-2)27 transgenic rat onto the Lewis background. 24 The female mRen2.Lewis rat is an estrogen-sensitive model, because ovariectomy significantly exacerbates the degree of hypertension and because estrogen replacement normalizes the blood pressure. 25 This model emulates the syndrome exhibited clinically in postmenopausal women.
Interestingly, in estrogen-depleted mRen2.Lewis rats, Yamaleyeva et al 26 reported that the renal expression of eNOS was attenuated, whereas nNOS content was increased. Subsequent treatment with the selective nNOS inhibitor N 5 -(1-imino-3-butenyl)-L-ornithine (L-VNIO) partially reversed the effects of oophorectomy on high blood pressure in the female mRen2.Lewis rat. 26 These authors speculated that L-VNIO may inhibit uncoupled nNOS to reduce the formation of superoxide resulting in a reduction in blood pressure. With this in mind, the current study was designed to investigate the hypothesis that suppression of the protective cardiac eNOS isoform with a concomitant reduction in NO production and/or an increase in the presumed deleterious nNOS isoform contributes to LV remodeling in the ovariectomized (OVX) mRen2.Lewis rats. In addition, we evaluated whether the shift in the cardiac nNOS pathway from an adaptive (NO-producing NOS) to a maladaptive NOS (reactive oxygen species [ROS]-producing) is attenuated by the nNOS inhibitor.
METHODS

Experimental model
Experiments were conducted in congenic female mRen2. Lewis rats obtained from the transgenic rat colony of the Hypertension and Vascular Research Center of Wake Forest University School of Medicine. All experimental procedures were approved by the animal care and use committee of Wake Forest University. Rats were weaned at 3 weeks of age and allowed to acclimate in a temperature-controlled, Association for Assessment and Accreditation of Laboratory AnimalY approved facility (12-h light/dark cycle), with free access to rat chow and tap water. At 4 weeks of age, rats were randomly assigned to undergo either bilateral oophorectomy (OVX; n = 15) or sham operation (sham; n = 19) performed under 2% isoflurane anesthesia, as previously described. 23 At age 11 weeks, the groups were further randomly divided to receive the specific nNOS inhibitor L-VNIO (Enzo Life Sciences International, Inc., Plymouth Meeting, PA) diluted in saline for a targeted dose of 0.5 mg/kg per day or pure saline as a vehicle control (VEH) both delivered IP (2.5 KL/h, 4 wk) via an osmotic minipump (ALZET 2ML4; Durect Corporation, Cupertino, CA) (sham + VEH, n = 9; sham + L-VNIO, n = 10; OVX + VEH, n = 6; OVX + L-VNIO, n = 9). 26 Systolic blood pressure (SBP) was monitored once weekly via tail-cuff plethysmography (NIBP-LE5001; Panlab, Barcelona, Spain), beginning with a training phase at 5 weeks of age and continuing through the termination of the study at 15 weeks of age. Serum estradiol was measured at the completion of the study to verify complete oophorectomy and confirm depletion of circulating estrogen with a minimal detection limit of 5 pg/mL (Polymedco, Cortlandt Manor, NY).
Echocardiographic evaluation
At 15 weeks of age, cardiac dimensions and function were assessed in anesthetized (ketamine/xylazine: 80/12 mg/kg) animals using a Philips 5500 echocardiograph (Philips Medical Systems, Andover, MA) and a 12-MHz phased array probe as previously described. 23 LV mass was calculated using a standard cube formula, which assumes a spherical LV geometry according to the formula: LV mass = 1.04 Â [(LVEDD + PWT + AWT) 3 Y LVEDD], where 1.04 is the specific gravity of muscle, and LVEDD is LV end-diastolic dimension, PWT is posterior wall thickness, and AWT is anterior wall thickness. Relative wall thickness (RWT) was calculated as: 2 Â PWT/LVEDD.
Morphometry and histopathology
Cardiac cross-sections, 2-mm thick, were fixed for 24 hours in 4% paraformaldehyde followed by dehydration in graded ethanols before being embedded into paraffin blocks. Slices (4-Km) were mounted onto Superfrost Plus (Fisher Scientific, Pittsburgh, PA) slides and stained with hematoxylin and eosin stain to measure a myocyte cross-sectional area. Approximately 100 cardiomyocytes from 2 sections per rat were analyzed at Â400 magnification using a Leica DM4000B microscope (Leica, Bannockburn, IL) with a tandem Leica DFC digital camera and Simple PCI 6.0 software. Additional slides were stained with picrosirius red to evaluate interstitial and perivascular collagen deposition within the tissue using a polarized dark-field microscopy (polarizing microscope system [Olympus, Center Valley, PA] equipped with a Digital SPOT RT, 3-pass capture, thermoelectrically cooled chargecoupled camera [SPOT Imaging Systems, Sterling Heights, MI] and SPOT Advanced software), as previously described. 27 Adobe Photoshop Creative Suite 3 (Adobe Inc, San Jose, CA) was used to determine the ratios of collagen-positive stained pixels to unstained pixels in each photomicrograph (four randomized quadrant field images per rat, magnified Â200).
In situ ROS production
In situ production of ROS was determined using dihydroethidium (DHE), which reacts with O 2 j yielding the fluorescent product 2-hydroxyethidium. Slices (three sections per rat) were cut from frozen cardiac cross-sections and mounted in slides. The sections were then incubated with 10 KM DHE (Invitrogen Molecular Probes, Carlsbad, CA) in a humidified, light-protected chamber for 30 minutes at 37-C, and then the nuclei were counterstained with 4 ¶,6-diamindino-2phenylindole (30 Kg/mL; Sigma-Aldrich, St. Louis, MO). Slides were then rinsed in phosphate-buffered saline, cover slipped, and analyzed at Â400 using a fluorescence microscope (Leica DM4000B; excitation, 510-550 nm; emission, 590 nm for DHE; excitation, 330-380 nm; emission, 420 nm for 4 ¶,6-diamindino-2-phenylindole) connected to a Leica DFC digital camera. The fluorescent signal intensities were analyzed within the heart using Simple PCI 6.0 software. All data are presented as average gray scale intensities T SEM.
Western blot hybridization
Cardiac microsomes were prepared, and protein concentrations were determined as previously reported. 23 Fifty micrograms of homogenate proteins was separated by sodium dodecyl sulfateYpolyacrylamide gel electrophoresis on a 7.5% acrylamide gel and transferred to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). Immunocomplexes were detected with an anti-nNOS (1:2000), anti-eNOS (1:500), antiYphospho-eNOS (1:1000; BD Transduction Laboratories, Franklin Lakes, NJ), sarcoplasmic-endoplasmic reticulum calcium ATPase 2 (1:1000 dilution; Abcam, Cambridge, MA), anti-phospholamban (PLB) (1:2000; Millipore, Temecula, CA), and antiYphospho-PLB Ser16 (1:5000; Millipore). To normalize the variability of protein loading, the antibody to elongation factor 1> (1:10,000 dilution; Millipore) or glyceraldehyde-3phosphate dehydrogenase (1:5000 dilution; Cell Signaling, Danvers, MA) was used as a loading control. The bound antibodies were resolved with a Super Signal West Pico chemiluminescent/enhancer kit (Pierce ECL Western Blotting Substrate; Pierce, Rockford, IL), exposed to Amersham Hyperfilm (Amersham Biosciences, Piscataway, NJ), and analyzed using densitometry. The resulting densities were corrected for background and expressed as arbitrary units normalized to the elongation factor 1> intensities. Human endothelial cell lysate (eNOS) and rat cerebrum cell lysate (nNOS) were used as positive controls (BD Transduction Laboratories).
Measurement of total biopterin and tetrahydrobiopterin levels
The biopterin profile of the cardiac tissue was measured by high-performance liquid chromatography with fluorescence detection, as previously documented. 28 The cardiac supernatant was subjected to protein assay and tetrahydrobiopterin (BH4) detection. Protein was removed from the supernatant by adding 10 KL of a 1:1 mixture of 1.5 M HClO 4 and 2 M H 3 PO 4 to 90 KL of extracts, followed by centrifugation. Total biopterin (BH4, dihydrobiopterin [BH2], and oxidized biopterin [B]) was determined by acid oxidation whereby 10 KL of 1% iodine and 2% potassium iodide in 1 M HCl solution were added to 90 KL of protein-free supernatant. BH2 plus B was determined by alkali oxidation by the addition of 10 KL of 1 M NaOH to 80 KL of the supernatant, followed by 10 KL of 1% iodine and 2% potassium iodide in 1 M NaOH solution. The acid oxidation samples were protected from light and incubated for 1 hour at room temperature. Five microliters of fresh ascorbic acid (20 mg/mL) was then added to samples to reduce iodine, and 20 KL of 1 M H 3 PO 4 was added to acidify the alkaline oxidation samples before the ascorbic acid. The samples were centrifuged, and 90 KL of the supernatant was injected into a 250-mm-long, 4.6-mm-inner diameter Spherisorb ODS-1 column (5-Km particle size; Alltech Associates, Inc, Deerfield, IL) isocratically eluted with a methanol/water (5:95, vol/vol) mobile phase running at a flow rate of 1.0 mL/minute. Fluorescence (350-nm excitation, 450-nm emission) was detected by a fluorescence detector (RF10AXL; Shimadzu Co, Columbia, MD). BH4 concentration was calculated by subtracting BH2 and B from total biopterins.
Nitrite measurements
Nitrite levels were measured using a chemiluminescencebased nitric oxide analyzer (Sievers, Inc; GE Analytical Instruments, Boulder, CO). Nitrite is reduced in a sample chamber to release NO, which then goes to a reaction chamber where it reacts with ozone to form a quasi-stable chemiluminescent species. The sample chamber contains sodium iodide in glacial acetic acid to reduce the nitrite. The amount of light detected on a photodiode is proportional to the amount of released NO and, hence, nitrite in the sample. The integral of the voltage recorded is proportional to the detected light. The values observed in this study are typical of these measurements. 29 In addition to variation due 
to sample handling and instrumentation, nitrite is influenced mostly by NOS function but also by diet. 29 Overall, the variability is small. For all measurements, standard curves were obtained and used for quantitative measurements.
Statistical analysis
All values are expressed as mean T SEM. For serial blood pressure measurements, a 2 Â 2 Â 2 Â 5 multivariate analysis of variance was conducted to determine the relationships between the four groups and the changes in blood pressure over the duration of the experiment. The differences in the blood pressure levels were modeled as interactions between procedure (sham vs OVX), treatment (VEH vs L-VNIO), before and after treatment, and time. The one four-way factorial analysis and the three three-way analyses indicated significant interactions between all the factors, which leads to further characterization of the differences after the treatment commenced using one-way analyses of variance and Bonferroni post hoc tests for each time point. For all other endpoints, two-way analysis of variance evaluated significant effects of estrogen or L-VNIO. Significant interactions between the groups were further characterized using Bonferroni post hoc tests. Analyses were performed using GraphPad Prism 5 (GraphPad, San Diego, CA) or SPSS (SPSS, Inc., Chicago, IL). Differences were considered significant at P G 0.05.
RESULTS
Removal of the ovaries was associated with an increase in body weight, independent of nNOS inhibition (Table 1) . Body weight in sham rats was not affected by treatment with L-VNIO. Estrogen depletion was confirmed by serum estradiol levels of less than 5 pg/mL and 27 T 1.6 pg/mL in OVX-and sham-treated mRen2.Lewis rats, respectively. Heart weight was increased in estrogen-deficient rats compared with intact rats, but this can be attributed to the increased body size of the OVX rats, given that heart weight and body weight were similar (Table 1) , as reported previously. 23 Progressive increases in SBP occurred in estrogen-intact and OVX mRen2.Lewis rats from 5 to 11 weeks ( Fig. 1 ). Similar to earlier findings, 25 substantial rises in blood pressure were observed by week 7 in OVX rats as compared with intact littermates (P G 0.0001). This exacerbated hypertension continued throughout the duration of the 15-week study (L 4,26 = 0.13, P G 0.0001). Commencement of chronic L-VNIO treatment led to modest reductions in SBP in both intact and OVX rats (L 1,29 = 0.58, P G 0.0001); however, the blood pressureYlowering effects of L-VNIO were not sustained in the estrogen-intact group (P 9 0.05).
The effects of estrogen and nNOS inhibition on echocardiographic-derived variables indicative of systolic and diastolic function are summarized in Table 2 and Figure 2 . Estrogen deficiency had no effect on the M-mode measurements of LV chamber dimensions or systolic function, as signified by the absence of changes in percent fractional shortening. Assessment of diastolic function using Doppler flow and Doppler tissue imaging showed impairment in LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; RWT, relative wall thickness; %FS, percent fractional shortening; E max , maximal early transmitral filling velocity; E dec slope , early filling deceleration slope; A max , maximal late transmitral filling velocity; E/A, earlyto-late transmitral filling ratio; e ¶, early mitral annular velocity; E/e ¶, early transmitral filling velocity-to-mitral annular velocity; a ¶, late mitral annular velocity; e ¶/a ¶, early-to-late mitral annular ratio; OVX, ovariectomized; L-VNIO, N 5 -(1-imino-3-butenyl)-L-ornithine. diastolic function in estrogen-deplete mRen2.Lewis rats as demonstrated by a 22% decrease in mitral annular descent (e ¶) in OVX rats despite no effect on systolic function (Fig. 2) . Furthermore, the early-to-late transmitral filling ratio tended to be blunted in estrogen-deficient rats compared with sham-operated littermates, because estrogen accounted for 9% of the variance in early-to-late transmitral filling ratio (estrogen: F 1,33 = 3.18, P = 0.08). Treatment with L-VNIO offered preservation of myocardial function as reflected in a 21% reduction in filling pressure, combined with a positive effect on myocardial relaxation represented as the ratio of early-tolate mitral annular velocity (P = 0.04; Table 2 ).
The reduction in myocardial relaxation in the OVX mRen2.Lewis rats was not associated with changes in the protein levels of sarcoplasmic-endoplasmic reticulum calcium ATPase 2 or phospholamban, key proteins in cytosolic Ca 2+ reuptake to the sarcoplasmic reticulum. Furthermore, the phosphorylation level of phospholamban was not altered by the removal of the ovaries or by L-VNIO (data not shown).
Although relative heart weights were similar among groups, estrogen and nNOS inhibition had notable effects on LV structure. There were increases in relative wall thickness in OVX rats relative to intact rats (estrogen effect: P G 0.05). Administration of L-VNIO partially reversed the increased wall thickness (L-VNIO: F 1,33 = 9.51, P = 0.004) from significantly elevated values after OVX (Table 2) . Moreover, ovariectomy in the mRen2.Lewis rats increased LV mass compared with intact littermates, and this remodeling effect was significantly attenuated by 4 weeks of nNOS inhibition (L-VNIO: F 1,33 = 4.65, P = 0.039). Importantly, these L-VNIOYmediated structural benefits were also observed in the estrogen-intact mRen2.Lewis rats, despite nominal changes in blood pressure.
Evaluation of LV hypertrophy after surgical estrogen depletion further showed that an increase in myocardial fibrosis was the primary trigger for remodeling rather than an increase in myocyte size. Perivascular collagen deposition was increased in OVX rats compared with intact littermates (P = 0.005), and this effect was improved by nNOS inhibition (L-VNIO effect: F 1,100 = 51.91, P G 0.0001) ( Fig. 3) . Although myocyte size was not altered by estrogen loss or L-VNIO (data not shown), DHE staining within myocytes revealed increased ROS generation in the OVX mRen2. Lewis rats compared with intact littermates (estrogen effect: F 1,266 = 48.8, P G 0.0001) ( Fig. 4) . Importantly, the 4-week administration of L-VNIO attenuated the DHE staining, particularly in OVX rats (L-VNIO effect: F 1,266 = 4.62, P = 0.0326).
A potential explanation for enhanced ROS generation in the hearts from OVX mRen2.Lewis rats is nNOS uncoupling, because estrogen influences the levels of BH4, an essential cofactor of NO synthase. 30, 31 To examine the potential role of BH4 degradation as the limiting factor in NO versus ROS production, we measured the cardiac biopterin profile (B + BH2 + BH4). Although there was no overall change in biopterin homeostasis in estrogen-deficient rats, the balance between BH4 and BH2 was shifted such that the concentration of BH4 was decreased and BH2 increased (Fig. 5 ). Specifically, estrogen accounted for 34% of the total variance in BH4 (P = 0.001) while simultaneously increasing cardiac concentrations of BH2 (estrogen: F 1,25 = 6.36, P = 0.019) ( Fig. 5 ). Specific nNOS inhibition with L-VNIO did not alter the cardiac biopterin profile.
In addition to the biopterin data, nitrite concentration, as an indicator of cardiac NO availability, showed that estrogen accounted for 21% of the total variance in tissue nitrite levels (estrogen: F 1,25 = 7.35, P = 0.012), whereas L-VNIO did not change the cardiac concentrations of nitrite and, hence, NO (Fig. 5) .
To determine whether estrogen or L-VNIO influences the cardiac NOS isoforms, we examined cardiac nNOS and eNOS expression. nNOS expression was increased 1.3-fold in the homogenates from OVX rats compared with estrogen-intact rats (estrogen: F 1,8 = 56.27, P G 0.005) (Fig. 6 ). The protein levels of eNOS were similar between OVX and intact littermates ( Fig. 6) as was the ratio of phosphorylated eNOS to total eNOS between the groups.
DISCUSSION
The primary finding of the current study is that in the OVX mRen2.Lewis rats, a model that emulates the cardiovascular phenotype in women after ovarian hormone loss, selective nNOS inhibition with L-VNIO attenuated cardiac superoxide production and limited cardiac remodeling, leading to improvements in diastolic function. As in previous reports, 23 diastolic function was worsened by removal of the ovaries. In the absence of estrogen, LV relaxation was impaired, whereas filling pressures tended to increase. These effects were coupled with myocardial structural alterations indicated by an increase in LV RWT as well as increased cardiac collagen deposition. Four weeks of targeted nNOS inhibition attenuated the diastolic dysfunction phenotype of the OVX mRen2. Lewis rats as revealed by echocardiogram-derived measures of myocardial relaxation and ventricular compliance. These functional changes were accompanied by reverse LV remodeling, because L-VNIO limited cardiac hypertrophy and perivascular collagen deposition in OVX mRen2.Lewis rats. Importantly, these data are the first to show that in the heart, OVX-elicited potentiation in ROS is abrogated by the nNOS inhibitor L-VNIO. These effects within the heart of the OVX mRen2.Lewis seem to be caused by diminished or oxidized BH4, the necessary cofactor for NOS activity, with concomitant increases in uncoupled nNOS and/or a reduction in NO production.
The adverse structural remodeling of the myocardium, indicated by increases in wall thickness, LV mass, and peri-vascular collagen, that contributes to the lusitropic dysfunction in the OVX mRen2.Lewis rat seems to be rooted at the level of extracellular matrix. Several studies showed that estrogen loss is accompanied by increases in tissue collagen deposition that may, in part, be a consequence of increased cardiac angiotensin II tissue content or activity in this model. 23 Because serum levels of aldosterone are increased in OVX mRen2.Lewis hypertensive rats, 23 this may contribute to collagen deposition within the heart. Other studies have implicated aldosterone as a potent profibrotic factor, 32<34 and in previous reports on mRen2.Lewis rats, 25 L-VNIO treatment was associated with a decrease in serum aldosterone to levels found in non-OVX rats. 26 It is plausible that the loss of estrogen accounts for the increased deposition, given that estrogen has been shown to regulate collagen turnover and fibroblast proliferation. 35, 36 Certainly, the exacerbated hypertension in the estrogen-deplete mRen2.Lewis rats could contribute to extracellular matrix remodeling and diastolic dysfunction.
Importantly, L-VNIO offered a degree of cardioprotection among OVX mRen2.Lewis rats that mitigated the diastolic dysfunction and attenuated LV remodeling. Because there were no overt changes in blood pressure in sham-operated rats at the end of the 4 weeks of treatment, the action of L-VNIO seems to be directed to the myocardium rather than the peripheral vasculature. Indeed, diastolic functional derangements have been reported in isolated cardiomyocytes from hypertensive mice. 37 Moreover, L-VNIO treatment in our sham-operated (estrogen-intact) rats improved myocardial relaxation and reduced wall thicknesses, perivascular fibrosis, and ROS generation in the absence of changes in SBP. In a recent report by Silberman at al, 37 hypertensive mice given either hydralazine or BH4 experienced equivalent blood pressure reductions, although improvements in diastolic function were detectable only in the BH4-treated mice. Taken together with our findings, these data implicate a direct role of cardiac NOS in the preservation of cardiac structure and diastolic function. Our data corroborate clinical and experimental studies that show cardiac functional improvements associated with decreased oxidative stress after blockade of the renin angiotensin system that are independent of blood pressure. 38<40 The loss of the estrogenic stimulus on BH4 synthesis may uncouple nNOS, shifting it to a maladaptive ROS-generating state. In the OVX mRen2.Lewis hypertensive rat, a discoordinate regulation of renal NOS isoforms was evident, with reduced renal cortical messenger RNA and protein levels of eNOS, whereas renal cortical nNOS messenger RNA and protein were increased. 26 In this situation, as in our current study, nNOS is presumed to transition from catalyzing NO formation to generating superoxide. 41, 42 Although the precise mechanism for this conversion of nNOS is not clear, it may reflect estrogen-sensitive regulation of guanosine triphosphate cyclohydrolase I, the rate-limiting enzyme of BH4 synthesis. 43 Thus, in the absence of estrogen, the nNOS cofactor, BH4, may be oxidized or decreased overall, leading to an increase in ROS at the biological expense of reduced NO. White et al 44 emphasized the importance of age-related decreases in requisite components of NOS activity while demonstrating that nNOS specifically is an estrogen target in coronary vessels that can lead to detrimental or beneficial effects depending on the surrounding milieu that determines the coupling state of the enzyme. In a coupled state, NOS is considered positive in that it generates NO. Alternatively, in situations where NOS becomes uncoupled, NOS activity can be detrimental by generating ROS.
This idea of Buncoupling[ is a rather novel phenomenon, which was first demonstrated in the heart and vascular beds predominantly related to eNOS. 45, 46 More recently, it has been shown that nNOS uncoupling in the heart may regulate cardiac function. 47<49 Specifically, nNOS stimulates cardiac O 2 j production, modulates cardiac nitrosoredox balance, and stimulates the development of diastolic dysfunction. 37 L-VNIO seems to have targeted this pathway because longstanding administration of the inhibitor reduced the increase in ROS production while improving diastolic function after oophorectomy. According to Babu and Griffith, 50 L-VNIO is a potent, mechanism-based inhibitor blocking the heme cofactor of NOS, which also shows a marked selectivity for nNOS. Typically, in the presence of nicotinamide adenine dinucleotide phosphate and O 2 , L-VNIO irreversibly inactivates nNOS through a Ca 2+ /calmodulin-dependent effect. In the absence of BH4, inhibition of nNOS activity by L-VNIO is increased. 50 It is plausible that estrogen depletion and the subsequent BH4 reduction may have augmented the inhibitory capacity of L-VNIO on nNOS. 50 Taken together, these findings support the notion that estrogen has a regulatory role in the maintenance of cardiac structure and diastolic function, in part, through its modulation of myocardial NO production or by direct attenuation of the profibrotic actions of ROS.
The present study has a few limitations. First, the pharmacological specificity of L-VNIO for nNOS as opposed to the other NOS isoforms is unconfirmed under the existing physiological setting. To adequately address the precise contribution of nNOS blockade to alterations in NOS activity and to improvements in cardiovascular endpoints, parallel studies using nonspecific and specific inhibitors of the other NOSs would be needed. Although this is beyond the scope of our current study, several ex vivo cardiomyocyte studies performed by others do indeed show that L-VNIO is specific for nNOS. The initial study by Babu and Griffith 50 found the K i of L-VNIO for nNOS to be 0.1 KM, compared with values at least 100 times higher in eNOS (12 KM) and inducible NOS (60 KM). Another study using isolated myocytes from wild-type and selective nNOS knockout mice shows that L-VNIOYtreated cells of wild-type mice have the same relaxation potential as that of cells rendered from knockout mice. 51 Elaborating on their previous work, Sears et al 52 also showed that L-VNIOYtreated cardiomyocytes from wild-type mice increase the sarcoplasmic reticulum Ca 2+ load to a similar degree as myocytes isolated from nNOS knockout mice. Therefore, taken together, with the increased expression of nNOS in hearts from OVX mRen2.Lewis rats and the abrogation of cardiac ROS production after administration of L-VNIO, these findings suggest that the in vivo administration of L-VNIO conferred specificity for nNOS rather than eNOS.
Second, the physiological perturbations from abrupt (via surgical manipulation) ovarian hormone loss in adult rodents are not analogous to that which occurs in middle-aged women after natural menopause. Although artificial or surgical menopause represents less than 13% of women (see the Web site: http://www.menopause.org), reports have also linked premenopausal oophorectomy with unfavorable health consequences including increased cardiovascular risk. 53, 54 As in humans, the mRen2.Lewis female rodent shows accelerated increases in blood pressure and LV hypertrophy after ovarian hormone depletion. This strain, therefore, provides a unique model to study the role of ovarian hormones, independent of age-related cardiovascular changes, in the pathogenesis of diastolic heart disease in a Bhigh-risk[ population.
CONCLUSION
In summary, we show that estrogen depletion, due to the removal of the ovaries, in mRen2.Lewis female rats exacerbates diastolic dysfunction while invoking functionally diminished myocardial relaxation and altered cardiac pathology including increased LV RWT and collagen deposition. These detrimental effects were significantly attenuated after the administration of a selective nNOS inhibitor, which we propose is due to the ability of L-VNIO to mitigate ROS generation. 
